Jeremy Clarke is currently a Director in GSK’s Global Manufacturing Technical Function supporting technology transfer, industrialisation and filing of late stage development candidates in the respiratory portfolio, life cycle management programmes for marketed products and external advocacy in the science and regulation of orally inhaled drug products (OIPs). Jeremy is a member of the Board of Directors of IPAC-RS and also co-chairs the Inhalation Focus Group of the Academy of Pharmaceutical Sciences. A pharmacist by training, Jeremy obtained his PhD in non-aqueous colloid & interface science at the Welsh School of Pharmacy, University of Cardiff. Following his doctorate studies, Jeremy joined Ciba-Geigy (Novartis) working on OIPs, where he advanced to leadership of the formulation development group. Subsequently, Jeremy joined Vectura where as Director of Respiratory Development, he had responsibility for both in-house and contract development programmes for OIPs. Jeremy then joined Pfizer at Sandwich as matrix/ line leader with responsibility for development of new products and technologies for both OIPs and oral solid dosage forms.
Where have all the Inhaled Biologics Gone?